drugset / Trial / NCT07176689
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Phase 4
Recruiting
50 enrolled
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
NaSingle-groupOpen-labelTreatment
Summary
This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.
Timeline
- Start
- 2025-09-17
- Primary completion
- 2031-01-14
- Completion
- 2031-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirogacestat | Small molecule | 150 mg | Oral |